Innovate UK

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

Dia Beta Labs is a biotechnology company dedicated to improving the lives of individuals with metabolic diseases. It operates from Ulster, where it has access to advanced facilities and a network of experts. The company's focus is on developing therapeutic agents to address the decline of pancreatic health in patients, with the goal of achieving more sustainable and effective weight loss than current options. Its discovery platform uses industry-standard methodologies and models to identify and advance lead molecules for animal research.

Keltic Pharma Therapeutics enhances drug discovery through innovative scientific research, resulting in a healthier future.

Chromatwist develops innovative fluorescent dyes that become visible under UV light. Their patented technology platform enables the creation of fluorophores used in bio-sensing (like flow cytometry) and bio-imaging (such as multiphoton microscopy) within the healthcare sector.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Lentitek is a cell and gene therapy company developing gene therapies and gene-modified cell therapies to broaden access to cures. It focuses on increasing the production yields of lentiviral vectors through its platform, using a novel promoter and proprietary production methods. The approach aims to deliver substantially higher yields, potentially reducing manufacturing costs and improving scalability for healthcare providers delivering gene therapies.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Founded in 2009, MedAnnex is a UK-based biotechnology company dedicated to developing first-in-class antibody therapies for treating cancers and autoimmune diseases. Its lead product, annexuzlimab, targets annexin-A1 to inhibit cancer cell growth and autoimmune condition development.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

Nuclera specializes in accelerating drug discovery by providing a protein prototyping system. Its eProtein Discovery™ platform enables scientists to rapidly produce and test proteins for research purposes.

Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

Monument Therapeutics is a biotechnology company focused on developing drugs for treating serious diseases of the central nervous system. Its innovative approach employs proprietary digital biomarkers to reduce patient heterogeneity, enabling more targeted neuroscience drug development in areas with unmet medical needs.

BSF Enterprise specializes in biotech solutions, focusing on cell-based tissue engineering. Its primary products include cultured meat, lab-grown leather, human corneas, collagen growth, and skin substitutes.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

SökerData is a biotechnology company that specializes in research and data analysis solutions focused on disease-related datasets. The company has developed a data visualization platform designed to analyze biomarkers in clinical outcomes across various demographics. This platform provides researchers with essential features and tools for interpreting large datasets, facilitating early drug discovery. By enabling researchers to better understand the impact of biomarkers on different populations, SökerData supports informed decision-making and enhances the comprehension of disease outcomes in diverse demographic groups.

Aelius Biotech specializes in developing models of the mucosal surfaces within the human body. Currently, they focus on simulating the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

CellRev is a biotechnology company specializing in process intensification for cell manufacturing. Its proprietary technology enables the transition from batch to continuous processing of adherent cells, increasing yields while reducing operating costs and capital expenditure.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Laverock Therapeutics develops a gene silencing platform for creating programmable, allogeneic cell therapies.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.

ZiO Health is a biotechnology company that develops pocket-sized devices featuring proprietary biosensor technology and machine learning algorithms. These devices enable real-time laboratory testing at the point-of-care, enhancing patient care by combining immediate results with individual patient profiles.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

FourPlus Immersive offer immersive software solutions for the life sciences sector, including skills & facility mapping & recruitment tools.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Aten Therapeutics specializes in developing novel therapeutic antibodies targeting fundamental control pathways associated with major diseases. Their experienced management team aims to extend and improve patients' lives by creating powerful new treatments.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative tools and technologies for drug screening and safety testing. Established in 2016, the company offers a range of products including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate employs advanced devices such as micro physiological systems and microfluidic technologies to facilitate research and development. One of its notable projects, the "Liver on chip," focuses on liver toxicity testing and integrates cellular reprogramming, stem cell research, and organ-on-chip technology. The company also provides services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

Founded in 2016, Five Alarm Bio is a biotechnology company based in Cambridge, UK. It focuses on drug discovery to develop anti-aging therapies using a small molecule approach, aiming to enhance the body's defenses against aging-related damage and diseases.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Founded in 2018 and based in Sheffield, UK, Rinri Therapeutics is a biotechnology company dedicated to developing regenerative stem cell-based therapies for treating hearing loss. Its innovative therapy aims to replace damaged sensory cells of the inner ear, restoring patients' hearing.

CryoLogyx is an early-stage biotechnology company that develops cryopreservation technology to produce frozen, ready-to-use cells for drug discovery, diagnostics, and cell therapies. Its approach protects cells during freezing using cryoprotectants, enabling viable cells to be stored and transported in formats tailored to researchers' needs. The technology aims to transform how cells are stored and delivered, ensuring cells and cell therapies are available in the desired format whenever needed.

Chromatwist develops innovative fluorescent dyes that become visible under UV light. Their patented technology platform enables the creation of fluorophores used in bio-sensing (like flow cytometry) and bio-imaging (such as multiphoton microscopy) within the healthcare sector.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

Aramune Technologies develops natural, plant-derived feed materials that can be mixed with standard animal feeds. These materials replace antimicrobial agents and promote growth in livestock.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Lumino is focused on enhancing mental health outcomes through the development of digital therapeutic programs. These programs specifically address various mental health concerns and incorporate techniques such as cognitive behavioral therapy (CBT) to help individuals manage their symptoms effectively. Supported by Innovate UK and the Oxford Academic Health Science Network, Lumino aims to leverage digital technology to deliver scalable mental health services, ultimately promoting healthier and happier lives for users.

Specializing in seed enhancement technologies, SilviBio aims to enhance tree planting efficiency by reducing seed losses. Their innovative products improve germination rates under dry conditions, supporting both forestry and agriculture sectors.

NovaBiotics Ltd. is a clinical-stage biotechnology company focused on designing and developing first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. Its lead product, Novexatin (NP213), is a topical treatment for fungal nail infections, affecting over 10% of the global population.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

DIOSynVax is a vaccine antigen design company focused on enhancing vaccine development through innovative technology. The company specializes in digitally designing, immune-optimized selecting, and synthesizing vaccines to improve protection against both emerging and re-emerging pathogens, including influenza, COVID-19, and viral hemorrhagic fevers. By leveraging its advanced technology, DIOSynVax aims to expedite the vaccine development process, ultimately enabling healthcare providers to treat patients more effectively and facilitate quicker recovery from various diseases. Through its efforts, DIOSynVax seeks to make significant advancements in public health by addressing the challenges posed by existing and future viruses.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

ExplantLab is a research organization based in Newcastle upon Tyne, United Kingdom. It focuses on investigating the connections between patients' genetics and the design, manufacturing, and performance of medical devices. The company aims to enhance the lives of patients by developing innovative medical solutions tailored to individual genetic profiles.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

CellRev is a biotechnology company specializing in process intensification for cell manufacturing. Its proprietary technology enables the transition from batch to continuous processing of adherent cells, increasing yields while reducing operating costs and capital expenditure.

Ixaka is a UK-based biotechnology company focused on developing advanced cell-based therapeutics to treat serious diseases. Its proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and modifying them within the body to improve their action, with potential applications across oncology, cardiovascular, neurological, ocular diseases, and genetic disorders.

Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

Aglaris specializes in the development of automated cell culture bioreactors aimed at enhancing the mass production of human stem cells. The company focuses on simplifying and streamlining cell and tissue culture processes, ensuring they are efficient and reliable. By automating these processes, Aglaris significantly reduces the need for human intervention, which in turn minimizes contamination risks associated with cell handling. The technology behind Aglaris's bioreactors is innovative and protected by international patents, positioning the company to play a crucial role in advancing regenerative medicine and cell therapies.

Nanna Therapeutics Limited, established in 2012 and headquartered in Cambridge, UK, is a biotechnology company focused on developing drugs for age-related diseases such as mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. As of April 2020, the company operates as a subsidiary of Astellas Pharma Europe Ltd. Nanna Therapeutics employs a unique approach by targeting fundamental cellular processes to create innovative treatments for these conditions, with a particular emphasis on mitochondria, the energy source in every cell. The company's proprietary drug discovery platform, TIME (Totally Integrated Medicines Engine), combines advanced technologies like microfluidics and artificial intelligence to accelerate drug development and disrupt traditional methods of creating new medicines.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

MediSieve Ltd. is a London-based medical device company specializing in Magnetic Blood Filtration (MBF) technology aimed at treating blood-borne diseases. Founded in 2014, the company has developed a system that utilizes a magnetic filter to physically remove infected blood cells from a patient's bloodstream. The process involves circulating blood through an external loop where targeted magnetic particles are infused, binding to disease-relevant targets. This filtered blood then passes through a magnetic filter that captures the particles and bound targets, allowing the unaffected blood to return to the patient without the particles entering their body. MediSieve's innovative approach is applicable to various conditions, including malaria, leukaemia, sepsis, and other blood-borne diseases, enhancing the efficacy and safety of existing therapies. The company operates out of the Imperial Incubator in White City, London, where it conducts product development and validation in its dedicated laboratory facilities.

Founded in 2012, Bionema specializes in researching, developing, and commercializing biopesticides. It focuses on providing chemical-free, organic crop protection solutions to horticulture, turf and amenity, forestry, and public health sectors. The company aims to enhance food security, increase crop yields, and promote sustainable agriculture by reducing reliance on synthetic pesticides.

Orbit Discovery is a biotechnology company specializing in peptide display technology to identify potential peptide drugs for chronic diseases. Its proprietary Orbit platform uses small beads linked with randomized peptide sequences to DNA, enabling screening tools for various disease types. The company focuses on establishing collaborative research platforms and internal drug discovery programs.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services. Founded in 2015, the company provides a range of preclinical screening services, with a particular focus on ion channel testing. Its offerings include cardiac safety screening, neuroscience assays, and translational assays, aimed at supporting pharmaceutical and bioscience clients globally. Metrion Biosciences employs highly skilled electrophysiology techniques and offers flexible business models, including fee-for-service and collaborative options. This versatility allows the company to cater to various medicinal chemistry optimization programs, ensuring comprehensive support throughout the drug discovery process.